Weekly Report on the Greater Health Industry: Getein Biotech and Dymind Biotech Announce Strategic Partnership; Everest Medicines Appoints Chief Medical Officer and Chief Product Officer

Getein Biotechnology Co., Ltd. and Dima Biotechnology Reach Strategic Cooperation

At the 2024 CACLP Chongqing Exhibition, two leading companies in the IVD field, Getein Biotechnology and Di Mai Biotechnology, announced a strategic partnership. Both parties will share resources, complement each other's strengths, and promote IVD technology innovation and market development. This powerful collaboration heralds the birth of a series of innovative medical products and services, bringing revolutionary changes to the global healthcare industry. The exhibited Metis800 Smart Series Assembly Line incorporates multiple technologies, enabling one-tube full blood testing. (Source: Arterial Network)

Everest Medicines Announces Appointment of Chief Medical Officer and Chief Product Officer to Further Strengthen Management Team

Everest Medicines Appoints Zeng Qingwen as Chief Medical Officer and Liang Xu as Chief Product Officer to Strengthen Leadership Team and Drive R&D and Commercialization. Ms. Zeng will oversee clinical development, while Mr. Liang will lead market and medical affairs strategies. This move aims to enhance the integration of R&D, clinical, medical, and marketing functions, reinforce the company’s leadership in areas such as nephrology and infectious diseases, and achieve commercial success. (Source: Arterial Network)

WuXi AppTec Plummets Nearly 7% in Afternoon Trading, with Transactions Exceeding 7.5 Billion Yuan

WuXi AppTec's Stock Price Plummets Nearly 7% in the Afternoon, with Trading Volume Exceeding 7.5 Billion Yuan, Triggering Strong Market Reaction. (Source: Arterial Network)

CreateNew Drug Concept Stocks Open with a Surge, JOINN Laboratories Hits Limit-Up at the Opening

Stocks Related to Innovative Drugs Surge at Opening, with JOINN Labs Hitting the Upper Limit, Hongbo Medicine Up More Than 15%, and Haoyuan Medicine, Hengrui Medicine Ranking High in Gains. This Indicates a Continuous Rise in Market Attention and Enthusiasm for Innovative Drugs. Investors Are Advised to Closely Monitor Investment Opportunities in Relevant Sectors While Paying Attention to Risk Control. (Source: China Securities Network)

Micro-Energy Medical Completes Pre-A Round Financing of Tens of Millions of Yuan

Recently, Micro-Energy Medical Technology Co., Ltd. (hereinafter referred to as "Micro-Energy Medical") announced the completion of a Pre-A round of financing worth tens of millions of yuan. This round of investment was led by Taiyu Investment, with participation from Shenzhen Guochuang QinZhi Angel Fund and Huagai Capital. HanYu Capital continued to serve as the exclusive financial advisor. (Source: Arterial Network)

Inspire Medical Completes Angel Round Financing

Intelligent Wireless Endoscope Manufacturer Suzhou InnoEndo Medical Technology Co., Ltd. (hereinafter referred to as "InnoEndo") has completed its angel round of financing. The investors include Guoqian Venture Capital, Relay Fund, and Suzhou Medical Device Industry Group. The funds from this round will be used for the research and development of the company's core products, intelligent wireless rigid and flexible endoscopes, capacity expansion, and market development, among others. (Source: Arterial Network)

Kezx Completes Tens of Millions of Yuan in Financing

High-Quality Small Nucleic Acid Raw Material Supplier Shanghai Kezx Biotechnology Co., Ltd. (hereinafter referred to as "Kezx") announced the completion of a multi-million-yuan financing round. This round was co-led by Jiale Capital and Guohai Innovation Capital, with Qifeng Capital serving as the exclusive financial advisor. The funds will be used for the research and development of new small nucleic acid delivery systems and the industrialization of small nucleic acid monomer raw materials. (Source: Arterial Network)

Beijing Errui Xinyue Successfully Completes Pre-A Round Financing

Recently, Beijing Errui Xinyue Technology Co., Ltd. ("Errui Xinyue" for short) announced the successful completion of a Pre-A round of financing worth tens of millions of yuan. This round of financing was exclusively led by the well-known investment institution Sanze Venture Capital. This significant development not only injects new vitality into the company’s continued growth but also marks the market's widespread recognition of Errui Xinyue's strong capabilities and broad prospects in the exosome technology field. (Source: Arterial Network)

Publication of the Winning Results for the 23-Provincial Hemodialysis Consumables Centralized Procurement: 157 Products from 55 Companies, with a Maximum Price Reduction of 74%

Recently, the Henan Provincial Medical Insurance Bureau issued an announcement: First, it disclosed the winning results of the inter-provincial alliance procurement for blood dialysis medical consumables; second, it announced the supply list of the selected products. The announcement period is from March 8 to March 12. This alliance procurement for blood dialysis consumables involved 23 provinces, with a total of 176 products participating in the bidding. Among them, 157 products were selected, resulting in an 89% selection rate. According to Rule One, 119 products were selected, accounting for 67.6% of the total, while 35 products were selected under Rule Two, making up 19.9% through price negotiation. Additionally, 19 products failed to be selected, including five invalid applications and four that did not pass the price negotiation. A total of 55 companies had their products selected, with the highest reduction rate for representative products reaching 74%. (Source: Menet)

Hebei Province Releases the "Notice on Price Regulation for Drugs Already Listed Online"

Hebei Province Issues the "Notice on Price Regulation of Listed Drugs", Implementing the Requirements of the National Healthcare Security Administration for "Four-Way Drug" Governance. The notice outlines arrangements for price regulation of listed drugs in the province. Hebei’s “Four-Way Drug” listed prices will be compared with national monitoring prices and adjusted downward, not upward, with adjustments required by March 20th. Companies that fail to reduce prices without valid reasons will be handled according to relevant regulations on dishonesty.(Source: Arterial Network)